Studies continue to show benefits of long-acting injections for HIV prevention

SEATTLE — Two studies presented at the Conference on Retroviruses and Opportunistic infections demonstrated high adherence levels and acceptability of long-acting, injectable PrEP for HIV prevention among varying groups of people.
One of the two studies found that 89% of Black cisgender men and transgender women who have sex with men adhered to a regimen of cabotegravir injections given every 8 weeks — a regimen that has been approved by the FDA for HIV prevention since 2021.
The other study, a much smaller one conducted among cisgender female adolescents in three southern African

SEATTLE — Two studies presented at the Conference on Retroviruses and Opportunistic infections demonstrated high adherence levels and acceptability of long-acting, injectable PrEP for HIV prevention among varying groups of people.
One of the two studies found that 89% of Black cisgender men and transgender women who have sex with men adhered to a regimen of cabotegravir injections given every 8 weeks — a regimen that has been approved by the FDA for HIV prevention since 2021.
The other study, a much smaller one conducted among cisgender female adolescents in three southern African